Souhaitez-vous accéder aux communiqués récents ?

Leuven, 1 March , 2016 - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for back of the eye...

ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial EvaluatingMultiple Doses of Ocriplasmin to induce a Total Posterior Vitreous Detachment in Patients with Non-Proliferative Diabetic...

Study planned to start in Q1 2016 Leuven, Belgium - 7 January 2016 - Oncurious NV, an oncology company focused on the development of innovative medicines for the treatment of pediatric tumors, today...

Importance of proper patient selection demonstrated  No new safety signals identified, majority of adverse events resolve  Leuven, November 18, 2015 - ThromboGenics NV (Euronext Brussels: THR), an...

20,000 patients have been treated with JETREA® globally since its launch Leuven, November 13, 2015 - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on...

ThromboGenics Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase II Study with JETREA® for the Treatment of Non-Proliferative Diabetic Retinopathy (CIRCLE) ...

Regulated information ThromboGenics Business Update - Q3 2015          US organization adapted for break-even from 2016 onwards Since launch, 20,000 patients treated globally with JETREA® ...

Regulated Information - Transparency Statement Leuven, Belgium, 10 September 2015 - Pursuant to Belgian transparency legislation (Law of 2 May 2007), ThromboGenics NV (Euronext Brussels: THR)...

Regulated information                                      US organisation right-sized to meet current market needstargeting break-even in US from 2016 ThromboGenics clinical and pre-clinical...

Leuven, June 26, 2015 - Oncurious NV, an oncology company focused on the development of innovative medicines for the treatment of pediatric tumors, today announces the appointment of Prof Dr Peter...